EXACT SCIENCES CORPO

EXAS

Real-time Estimate - 05/26 02:18:02 pm
50.27USD	+3.80%

Turn to zoom

Prev.	48.4300
Open	49.0100
High	51.0100
Low	47.9000
Volume	1 710 715

05/11	Transcript : Exact Sciences Corporation Presents at Bank of America 2022...
05/02	Exact Sciences to participate in May investor conference
05/02	Exact Sciences Corporation completed the acquisition of Omicera Diagnostics...
04/29	Exact Sciences Corporation Receives a Shareholder Proposal from James McRitchie

	Short Term	Mid-Term	Long Term
Trend	Bearish	Bearish	Bearish
Resistance	59,3	66,5	75,6
Spread/Res.	-17%	-26%	-34%
Spread/Supp.	3,4%	3,4%	17%
Support	47,9	47,9	42,4

Sales 2022	2 024 M - -
Net income 2022	-760 M - -
Net Debt 2022	1 963 M - -
P/E ratio 2022	-11,3x
Yield 2022	-

Capitalization	8 521 M 8 521 M -
EV / Sales 2022	5,18x
EV / Sales 2023	4,53x
Nbr of Employees	6 460
Free-Float	99,1%

Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19...

>> Read more

Sector :

Bio Diagnostics & Testing

Calendar :

2022-06-09 Shareholder meeting

Trading Rating :

Investor Rating :

Sell Buy
Mean consensus	BUY
Number of Analysts	17
Last Close Price	48,43 $
Average target price	96,06 $
Spread / Average Target	98,4%